Biopharmaceutical company Pharmazz and Sun Pharmaceutical Industries have signed a licence agreement for the marketing of Tyvalzi (Sovateltide) in India.
Pharmazz developed the first-of-its-kind drug to treat cerebral ischemic stroke.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Sun Pharma received marketing rights for Sovateltide in the country under the Tyvalzi brand name. The drug can be given up to 24 hours following symptom onset.
Sun Pharma will make upfront, milestone and royalty payments to Pharmazz.
Sun Pharma India business CEO Kirti Ganorkar stated: “The Phase III clinical trial for Tyvalzi conducted in India demonstrated statistically and clinically meaningful improvement in neurological outcomes in ischemic stroke.
“Tyvalzi is a first-in-class innovative drug which can help improve the quality of life of stroke patients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“The current treatment options provide a narrow time window of four to five hours, limiting its use in most patients.”
Tyvalzi acts on the neural progenitor cells and boosts neurovascular remodelling by creating new neurons and blood vessels.
The drug also offers protection for neural mitochondria and boosts their biogenesis.
Acute cerebral ischemic stroke is a condition in which the brain’s blood supply is cut off, depriving brain tissue of oxygen and nutrients. This can cause damage to the brain, neurological issues or death.
